Paul E. Goss

15.7k total citations · 1 hit paper
85 papers, 6.2k citations indexed

About

Paul E. Goss is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, Paul E. Goss has authored 85 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Genetics, 36 papers in Oncology and 28 papers in Cancer Research. Recurrent topics in Paul E. Goss's work include Estrogen and related hormone effects (39 papers), Breast Cancer Treatment Studies (23 papers) and Cancer Risks and Factors (10 papers). Paul E. Goss is often cited by papers focused on Estrogen and related hormone effects (39 papers), Breast Cancer Treatment Studies (23 papers) and Cancer Risks and Factors (10 papers). Paul E. Goss collaborates with scholars based in Canada, United States and United Kingdom. Paul E. Goss's co-authors include Mark Clemons, Kathrin Strasser, Lois E. Shepherd, R. Charles Coombes, Dongsheng Tu, Mitch Dowsett, James N. Ingle, Paula D. Ryan, Kathleen I. Pritchard and James W. Dennis and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Paul E. Goss

83 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Estrogen and the Risk of Breast Cancer

2001 830 citations Paul E. Goss et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul E. Goss Canada	39	3.0k	2.5k	1.9k	1.6k	849	85	6.2k
Trevor J. Powles United Kingdom	32	2.6k 0.9×	2.7k 1.1×	1.6k 0.8×	1.1k 0.7×	478 0.6×	65	5.2k
Carol J. Fabian United States	37	1.9k 0.7×	2.8k 1.1×	1.7k 0.9×	1.2k 0.8×	684 0.8×	171	5.8k
V. Craig Jordan United States	57	7.3k 2.5×	3.3k 1.3×	2.1k 1.1×	4.1k 2.5×	620 0.7×	159	11.3k
Harold A. Harvey United States	43	1.6k 0.6×	2.3k 0.9×	864 0.5×	1.3k 0.8×	848 1.0×	130	5.0k
Bernardo Bonanni Italy	38	1.9k 0.6×	2.4k 1.0×	2.0k 1.0×	2.3k 1.4×	584 0.7×	189	5.8k
C. Kent Osborne United States	42	2.9k 1.0×	3.8k 1.5×	2.4k 1.2×	2.8k 1.8×	1.0k 1.2×	104	7.4k
Yasuhiro Miki Japan	45	2.5k 0.8×	2.2k 0.9×	1.6k 0.8×	2.8k 1.7×	1.1k 1.3×	248	6.7k
Ernst A. Lien Norway	37	2.0k 0.7×	1.3k 0.5×	646 0.3×	930 0.6×	271 0.3×	81	4.1k
Andrea DeCensi Italy	51	2.7k 0.9×	3.7k 1.5×	2.5k 1.3×	4.0k 2.5×	1.2k 1.5×	246	9.2k
Elizabeth Folkerd United Kingdom	36	1.7k 0.6×	1.4k 0.6×	995 0.5×	1.0k 0.7×	1.7k 2.0×	90	5.1k

Countries citing papers authored by Paul E. Goss

Since Specialization

Citations

This map shows the geographic impact of Paul E. Goss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul E. Goss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul E. Goss more than expected).

Fields of papers citing papers by Paul E. Goss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul E. Goss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul E. Goss. The network helps show where Paul E. Goss may publish in the future.

Co-authorship network of co-authors of Paul E. Goss

This figure shows the co-authorship network connecting the top 25 collaborators of Paul E. Goss. A scholar is included among the top collaborators of Paul E. Goss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul E. Goss. Paul E. Goss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ho, Ming‐Fen, Edroaldo Lummertz da Rocha, Cheng Zhang, et al.. (2018). TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor κB p65: Single Nucleotide Polymorphism and Estrogen Dependence. Journal of Pharmacology and Experimental Therapeutics. 365(3). 700–710. 7 indexed citations

Liedke, Pedro Emanuel Rubini, Dongsheng Tu, Lois E. Shepherd, et al.. (2016). New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole – Analyses from NCIC CTG MA.17. The Breast. 27. 99–104. 4 indexed citations

Goss, Paul E., J. N. Ingle, Silvana Martino, et al.. (2012). Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Annals of Oncology. 24(2). 355–361. 60 indexed citations

Cheung, Angela M., Lianne Tile, Sandhya Pruthi, et al.. (2012). Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. The Lancet Oncology. 13(3). 275–284. 78 indexed citations

Vogl, Steven E., et al.. (2012). Characterization of patients who received further adjuvant endocrine therapy after 5 years of aromatase inhibitors (AIs): NCIC CTG MA 27.. Journal of Clinical Oncology. 30(15_suppl). e11005–e11005.

Parulekar, Wendy R., Judy‐Anne W. Chapman, Lois E. Shepherd, et al.. (2012). Impact of concurrent (CON) and sequential (SEQ) radiotherapy (RT) with adjuvant aromatase inhibitors (AI) in early-stage breast cancer (EBC): NCIC CTG MA.27.. Journal of Clinical Oncology. 30(15_suppl). 500–500. 2 indexed citations

Joffe, Hadine, Ann Partridge, Anita Giobbie‐Hurder, et al.. (2010). Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes. Menopause The Journal of The North American Menopause Society. 17(5). 908–916. 32 indexed citations

Ma, Xiaojun, Ranelle Salunga, Sonika Dahiya, et al.. (2008). A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clinical Cancer Research. 14(9). 2601–2608. 227 indexed citations

Cigler, Tessa & Paul E. Goss. (2007). Breast Cancer Adjuvant Endocrine Therapy. The Cancer Journal. 13(3). 148–155. 13 indexed citations

10.

Pritchard, Kathleen I., Paul E. Goss, & Lois E. Shepherd. (2006). The extended adjuvant NCIC CTG MA.17 trials: Initial and rerandomization studies. The Breast. 15(1). 14–20. 6 indexed citations

11.

Wasan, Kishor M., Paul E. Goss, P. Haydn Pritchard, et al.. (2005). The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Annals of Oncology. 16(5). 707–715. 145 indexed citations

12.

Goss, Paul E. & Kathrin Strasser. (2002). Tamoxifen Resistant and Refractory Breast Cancer. Drugs. 62(6). 957–966. 24 indexed citations

13.

Clemons, M., et al.. (2000). Breast cancer risk following irradiation for Hodgkin’s disease. Cancer Treatment Reviews. 26(4). 291–302. 75 indexed citations

14.

Chan, Andrew K., et al.. (2000). Breast cancer in women ≤35 years: Review of 1002 cases from a single institution. Annals of Oncology. 11(10). 1255–1262. 57 indexed citations

15.

Warner, Elizabeth, William D. Foulkes, Pamela J. Goodwin, et al.. (1999). Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer. JNCI Journal of the National Cancer Institute. 91(14). 1241–1247. 306 indexed citations

16.

Peng, Hongqi, Ling Liu, Paul E. Goss, Denis Bailey, & David Hogg. (1999). Chromosomal deletions occur in restricted regions of 5q in testicular germ cell cancer. Oncogene. 18(21). 3277–3283. 19 indexed citations

17.

Goss, Paul E., et al.. (1998). Current perspectives on radiation-induced breast cancer.. Journal of Clinical Oncology. 16(1). 338–347. 65 indexed citations

18.

Goss, Paul E., et al.. (1994). A phase I study of swainsonine in patients with advanced malignancies.. PubMed. 54(6). 1450–7. 106 indexed citations

19.

Goss, Paul E., Frances A. Shepherd, Jonathan Scott, et al.. (1991). Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: Preliminary report of a phase II study. Annals of Oncology. 2. 43–46. 19 indexed citations

20.

Stewart, A. Keith, Frances A. Shepherd, Paul E. Goss, et al.. (1991). Gastrointestinal Non-Hodgkin's Lymphoma. Leukemia & lymphoma. 4(3). 167–176. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact